Drug Combination Recommendation Model for Systemic Lupus Erythematosus and Antiphospholipid Syndrome
Pharmaceuticals · 19.08.2025 · 18 (8) · 1224
DOI: 10.3390/ph18081224 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 19.08.2025. Verfasst von Ling Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Computer Science and Technology, School of Computer Science, Northeast Electric Power University, Jilin City 132013, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Development Plan of Jilin Province, China.
Abstract (Originalsprache)
Background
Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) are two common autoimmune disorders for which the choice of drug regimen is clinically crucial. However, due to drug-drug interactions and individual differences, the therapeutic process faces greater risks.
Methods
In this study, we propose a drug recommendation model that combines drug combination frequency, risk assessment, and genetic interaction information with the aim of providing personalized, low-risk treatment options for patients with lupus erythematosus and antiphospholipid syndrome. We extracted drug combination frequencies and drug-gene interaction information from data sources, such as the MIMIC-III clinical database, Drug Bank, and Gene Expression Omnibus. The model comprehensively evaluates the frequency of drug combinations, the risk level, and the gene interaction information through a greedy algorithm to recommend the optimal drug alternatives.
Results
The experimental results show that the model is able to effectively reduce the potential risk between drugs while ensuring the drug treatment effect. In addition, the performance evaluation of the drug recommendation model shows that the model performs well under different drug combinations and clinical scenarios, and can provide clinicians with effective drug substitution suggestions.
Conclusions
This study provides an important theoretical basis and technical support for advancing the realization of personalized therapy and precision medicine.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Computer Science and Technology, School of Computer Science, Northeast Electric Power University, Jilin City 132013, China.
- Data Science Laboratory, Faculty of Information Technology, Ton Duc Thang University, Ho Chi Minh City 700000, Vietnam.
- Biomedical Engineering Institute, Chiang Mai University, Chiang Mai 50200, Thailand.
- Department of Computer Science, College of Electrical and Computer Engineering, Chungbuk National University, Cheongju 28644, Republic of Korea.
ORCID-Profile: Ling Wang, Tie Hua Zhou, Keun Ho Ryu
Förderung
- Science and Technology Development Plan of Jilin Province, China
Zitieren
APA
Wang, L., Zhang, Z., Zhang, Z., Zhou, T. H., & Ryu, K. H. (2025). Drug Combination Recommendation Model for Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Pharmaceuticals, 18(8), 1224. https://doi.org/10.3390/ph18081224
Vancouver
Wang L, Zhang Z, Zhang Z, Zhou TH, Ryu KH. Drug Combination Recommendation Model for Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Pharmaceuticals. 2025;18(8):1224. doi:10.3390/ph18081224
BibTeX
@article{Wang2025,
author = {Wang, Ling and Zhang, Zhengyang and Zhang, Ziheng and Zhou, Tie Hua and Ryu, Keun Ho},
title = {Drug Combination Recommendation Model for Systemic Lupus Erythematosus and Antiphospholipid Syndrome},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {8},
pages = {1224},
doi = {10.3390/ph18081224}
}
EUVIMED